Clinical trials: SARS-CoV 2
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT05629962
- Testing
- Bemnifosbuvir (BEM)
- Where
- 263 sites in United States, Argentina and 17 more
- Volunteers
- 2,285 people
- Sponsor
- Atea Pharmaceuticals, Inc.
SARS-CoV Infection, Covid19
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this…
- Trial name
- NCT04961541
- Testing
- ICC Vaccine, qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant, SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
- Where
- 10 sites in Australia
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon